Taipei, Taiwan, September 10, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader headquartered in Taiwan, announced its unaudited consolidated revenue for August 2024, totaling NT$1,325 million. This reflects a 11.9% increase compared to the same period last year.
The company’s export revenue saw a 14% year-over-year (YoY) growth, driven by a strong demand for oncology products outside the US market. Revenue from Asia also increased by approx. 10% YoY, with Thailand experiencing an over 180% YoY jump, primarily due to the recent acquisition of Teva Pharma Thailand.
On September 5, 2024, Lotus announced its second Southeast Asian acquisition of the year, acquiring the leading anti-inflammatory product Alpha Choay® in Vietnam and Cambodia. In 2023, Alpha Choay® generated over US$22 million in sales across these regions. Lotus anticipates recognizing revenue from Alpha Choay® in the first half of 2025, pending antitrust approval from the Vietnam Competition Commission.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com